Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
High Grade B-cell Lymphoma (HGBCL): early-phase trial registry
1 of 4 indexed High Grade B-cell Lymphoma (HGBCL) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
High Grade B-cell Lymphoma (HGBCL): 4 US clinical trials tracked, 1 recruiting.
High Grade B-cell Lymphoma (HGBCL) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Miltenyi Biomedicine, running 1 of these trials.
Enrollment posture brief
Registry condition high-grade-b-cell-lymphoma-hgbcl
OPEN 1 | RECR 25% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
High Grade B-cell Lymphoma (HGBCL) lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for High Grade B-cell Lymphoma (HGBCL) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
High Grade B-cell Lymphoma (HGBCL) is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine
NCT04792489
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Genmab
NCT03625037
Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy
H. Lee Moffitt Cancer Center and Research Institute
NCT04745559
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
Kite, A Gilead Company
NCT02348216
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on High Grade B-cell Lymphoma (HGBCL) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on High Grade B-cell Lymphoma (HGBCL) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this High Grade B-cell Lymphoma (HGBCL) page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 High Grade B-cell Lymphoma (HGBCL) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Miltenyi Biomedicine sponsors the most High Grade B-cell Lymphoma (HGBCL) trials on record, review their full trial history before evaluating a specific study. See Miltenyi Biomedicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This High Grade B-cell Lymphoma (HGBCL) condition card totals 4 registered trials; most-linked intervention Fludarabine; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.